Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr. Andreas Meudt
Vice President / General Manager Product Line Exclusive Synthesis at Evonik Industries AG
Frankfurt Am Main Area, Germany
General Management
Custom Manufacturing
Exclusive Synthesis
API and Intermediates
R&D Management
Innovation Management
New Business Development
Sales and Marketing Management
Public Relations
Change Management
Specialties: PhD in Organic Chemistry - Innovation, New Technologies
MBA (WHU / Northwestern University)
Sales and Marketing - Growth strategies in chemical / pharmaceutical industries
Products & Solutions
INDUSTRY TEAMS
PHARMA
We love all the challenges our customers face today and in the future when it comes to translating ideas into successful, market-ready solutions for the pharmaceuticals sector.
Need a partner for innovative drug delivery technologies for targeted, time-controlled release of active ingredients? Looking for proven know-how in custom manufacturing of intermediates and active pharmaceutical ingredients (APIs)? Or how about harnessing the experience of a leading global catalyst supplier who can tailor catalysts to the specific needs of customers manufacturing APIs and intermediates? We would love to help you with our creativity, passion and expertise.
The website is accessible on:
www.evonik.com/pharma
Innovation Pharmaceuticals Signs Drug Supply Contract with Evonik to Bulk Produce Commercial-Grade Brilacidin
BEVERLY, MA – April 23, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has signed a drug supply contract with Evonik Corporation, a world leader in specialty chemicals, for the bulk production of commercial-grade Brilacidin to prepare for, as well as expedite, its continued clinical development.
Brilacidin is a versatile compound exhibiting broad therapeutic potential in a new chemical class called defensin-mimetics. The drug candidate, with unique and robust immunomodulatory, anti-inflammatory, and antibacterial properties, has successfully been tested in clinical trials in oral mucositis, ulcerative proctitis/ulcerative proctosigmoiditis, and serious skin infections.
“We are delighted to have been selected by Innovation Pharmaceuticals to scale up and industrialize the production of Brilacidin, a phase 3 drug compound advancing in multiple development programs under Fast Track designations and look forward to contribute to the success of this franchise,” said Dr. Andreas Meudt, Vice President, Product Line Exclusive Synthesis at Evonik’s Health Care Business Line.
Securing a commercial-grade drug supply of Brilacidin with a leading Contract Development and Manufacturing Organization (CDMO), such as Evonik, is an important and necessary step that will enable Innovation Pharmaceuticals to more rapidly advance the Brilacidin Franchise, toward getting much-needed treatments to patients.
“We are pleased to have Evonik’s expertise applied to the CMC efforts integral to moving our Brilacidin programs toward the finish line,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “We anticipate this drug substance, to be manufactured to the high standards and philosophy of Quality by Design (QbD), will provide for our long-term needs across multiple anchored clinical indications in the Brilacidin Franchise.”
About Evonik Corporation
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion. More information is available at: www.evonik.com.
Agreed. And our first partnership will be for K and with Novartis. All IMO.
0.77 and 272,236
There's a room for .72 and don't worry they will take them...
The day still long, wait and see...
Some hints:
1- PoC: xyz company Oncology also conducts “Proof of Concept” trials, which are a mixture of Phase I and II studies. These small-scale studies help give us an early read on a drug’s safety and efficacy to find and advance the most promising drug candidates.
2- xyz company well involved in the P53 trials
GO IPIX...
I believe a big surprise is in the making IMHO.
GO IPIX....
4 weeks (total duration 11 weeks = 7 weeks + 4 weeks)
Nerby, was this your message in the support site:"Wondering if any readers have perhaps been involved in the Phase IIb clinical trial for Prurisol in about 33 locations across the US. If yes can you advise your impressions of the treatment? Thanks!"
IPIX green today!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
And the 100k shares ask order disappeared...
And Green we are .72 now.
It will be today, 31000 Bid at .71.
Go ...IPIX
And Green we're going.
Go IPIX..............
Yes, I'm still seeing CTIX in my brokerage account.
we're done with .96 what about .97?
And what about .96... Go CTIX
Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment
http://finance.yahoo.com/news/cellceutix-reports-very-encouraging-interim-140000035.html
Small correction, the twice daily is not for the first week only, it is for the first two weeks.
LN, This what I got as result for the "Moderate UP" search, so you can try it and you wil find may results for Mild to Moderate Ulcerative Colitis:
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
mild-to-moderate UP/UPS. The trial comprises three sequential cohorts (6 patients per cohort), with …
Cellceutix Receives Update on First Patient Enrollment in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis
in adults with active, mild to moderate UP or UPS present for at least three months prior to …
Cellceutix Receives Update on First Patient Enrollment in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis
in adults with active, mild to moderate UP or UPS present for at least three months prior to …
Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease
(Cohort B) and 200 mg (Cohort C)—in patients with active mild-to-moderate UP/UPS. Brilacidin is given …
Scott Gottlieb is nominated to run the world's largest drug regulator.
quote
"...Trump nominated Scott Gottlieb. Among other things, he's been a deputy commissioner and a director of medical policy development at the FDA....Gottlieb wants to speed approval of new drugs. He's pointed out that the FDA's prioritizing of consumer protection means it has often neglected guiding new medical innovations to market. He wants to help change the focus of the regulator to better balance blocking potentially harmful products with the harm of potentially lifesaving products never getting to people who need them.
And that too could prove to be very good for small biotech companies working on bringing new drugs to market... especially those working on breakthrough platforms..."
Clinicaltrial updated yesterday for B-OM. 12 recruiting locations and one not yet recruiting.
GO CTIx....
AACR meeting and CTIX:
www.abstractsonline.com/pp8/#!/4292/presentation/3876
Because all of your lately posting and because CTIX is starting the K2-OC not the way that you want, I'll be selling all my CTIX shares first thing on Monday.
Thanks "To infinity and beyond" you're the king.
Just I want to add: ...Go CTIX.
Link: https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=3
A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
This study is not yet open for participant recruitment. (see Contacts and Locations)
And you forgot the royalties (even if they sell all their shares).
Nice reading and Brilacidin day will be coming shortly:
Quote:"So at the congressional hearing on superbugs in June, Beth Bell, director of the Centers for Disease Control’s National Center for Emerging and Zoonotic Infectious Diseases, testified that “Antibiotic resistance is perhaps the single most important infectious disease threat of our time. Every year, more than 2 million people in the United States get infections that are resistant to antibiotics, and at least 23,000 people die as a result… Modern medicine is at stake.”
Still, those are just numbers, right? Well, perhaps think of it this way: Every day, more than 60 people in the United States die because they can’t fight off an infection that is resistant to antibiotics. Sixty people a day!
We need new antibiotics as soon as we can get them, but we also need smarter antibiotics, ones that work in ways that bacteria will find it more difficult to build resistance to.
And if you still think you’re going to be OK and beat the odds on getting an infection an antibiotic can’t defeat, know this: Mother Nature is against you.
Exactly what do we need now?
Antibiotic development has been on the wane for several decades because modern Big Pharma companies found they could make billions off drugs that treat cancer or rare diseases but could only make millions off antibiotics. Furthermore, there used to be something of a glut of antibiotics.
That has all flipped. Congress has given drug companies big incentives in recent years, including exclusivities and longer patent times, if they choose to develop new antibiotics.
The incentive is now there, and drug companies are scrambling. After all, an effective broad-range antibiotic could bring in billions of dollars a year.
If you’re an investor, you should love companies trying to make new antibiotics.
To your health and wealth,
Stephen L. Petranek"
Just watch MAX...
This is what I found re the Trial.
http://adisinsight.springer.com/trials/700251998
The Brilacidin-UC trial will be conducted in Europe.
Quote:
"This European trial will investigate the safety and tolerability of brilacidin as a potential ... Drugs Brilacidin (Primary); Indications Ulcerative colitis; Focus Adverse ..."
Nice read article on SA: CTIX & Partnership
http://seekingalpha.com/article/3980357-hey-cellceutix-get-partner?auth_param=mpec:1bld8oh:4b0474c964aa3787e3fac6e9bff5e3fe&uprof=45
Go CTIX...
Didn't find it anywhere. Please provide link.
Here's more:
1- Canada has the highest UC prevalence in the world.
2- ~ 104,000 Canadians live with UC.
3- Every year 4,500 Canadians are newly diagnosed with UC.
4- 12.9% new cases of UC for every 100,000 Canadians.
5- 51% had to be hospitalized.
6- 16% had surgery.
Source Abbvie.
Go to CTIX...
If I tell you it is CANADA. What will add for you?
Go CTIX...
Democracy:
you have a vote: CEO not credible
I have a vote: CEO is credible.
So -1+1 = 0.
So new investor has to do his DD and act accordingly.
Go Ctix...
After DD, I believe B-UP will be in Canada. Go CTIX... Romaa